Chimerix Responds to Rubric Capital Management
November 10, 2022 16:30 ET
|
Chimerix, Inc.
DURHAM, N.C., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients...
Chimerix Reports Third Quarter 2022 Financial Results and Provides Operational Update
November 03, 2022 07:00 ET
|
Chimerix, Inc.
– ONC201 Phase 3 ACTION Study On-Track to Open Enrollment in November – – Meeting with U.S. Food and Drug Administration (FDA) Set for Fourth Quarter – – Strong Financial Position with ~$285...
Chimerix to Report Third Quarter 2022 Financial Results and Provide an Operational Update on November 3, 2022
October 27, 2022 16:30 ET
|
Chimerix, Inc.
DURHAM, N.C., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend lives of patients...
Chimerix Announces Closing of TEMBEXA Sale to Emergent BioSolutions
September 26, 2022 16:05 ET
|
Chimerix, Inc.
- $238 Million in Upfront Payment Received at Closing with Additional $136.5 Million in Potential Milestone Payments Plus Royalties - DURHAM, N.C., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Chimerix,...
Chimerix to Present at H.C. Wainwright 24th Annual Global Investment Conference
September 06, 2022 07:00 ET
|
Chimerix, Inc.
DURHAM, N.C., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of...
Chimerix Awarded BARDA Contract for TEMBEXA as Medical Countermeasure for Smallpox
August 29, 2022 10:45 ET
|
Chimerix, Inc.
- Initial Procurement of 319,000 Treatment Courses for $115M with Additional Procurements at BARDA’s Discretion Over 10 Years – - Emergent BioSolutions, Inc. Payment Increases to $238M Upfront...
Chimerix Reports Second Quarter 2022 Financial Results and Provides Operational Update
August 08, 2022 16:01 ET
|
Chimerix, Inc.
– ONC201 Phase 3 ACTION Study Planned to Initiate This Year – –~$32M in Revenue from International TEMBEXA Agreements Recently Recognized– – U.S. Anti-Trust Clearance Obtained for Sale of TEMBEXA to...
Chimerix Appoints Christopher L. Jordan as Vice President, Regulatory Affairs
August 08, 2022 07:00 ET
|
Chimerix, Inc.
DURHAM, N.C., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of...
Chimerix to Present at Wedbush PacGrow Healthcare Conference
August 02, 2022 07:00 ET
|
Chimerix, Inc.
DURHAM, N.C., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend lives of patients...
Chimerix to Report Second Quarter 2022 Financial Results and Provide an Operational Update on August 8, 2022
August 01, 2022 16:01 ET
|
Chimerix, Inc.
DURHAM, N.C., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend lives of patients...